ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) Short Interest Up 33.0% in September

ZyVersa Therapeutics, Inc. (NASDAQ:ZVSA) was the target of a large increase in short interest during the month of September. As of September 30th, there was short interest totalling 23,800 shares, an increase of 33.0% from the September 15th total of 17,900 shares. Based on an average daily volume of 95,500 shares, the days-to-cover ratio is presently 0.2 days. Approximately 2.2% of the shares of the company are sold short.

ZyVersa Therapeutics Price Performance

Shares of ZVSA stock opened at $2.32 on Monday. ZyVersa Therapeutics has a fifty-two week low of $2.08 and a fifty-two week high of $48.69. The stock’s 50-day simple moving average is $2.64 and its 200-day simple moving average is $4.19.

ZyVersa Therapeutics (NASDAQ:ZVSA) last issued its quarterly earnings results on Friday, August 9th. The company reported ($3.31) earnings per share for the quarter, topping the consensus estimate of ($5.20) by $1.89. As a group, equities analysts predict that ZyVersa Therapeutics will post -22.7 earnings per share for the current fiscal year.

About ZyVersa Therapeutics

ZyVersa Therapeutics, Inc, a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial to the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, IgA neuropathy, pancreatic cancer, Parkinson's and Huntington's disease, atherosclerosis, Alzheimer's disease, and obesity.